Spike mutation (S: L455S) yog qhov kev hloov pauv ntawm JN.1 sub-variant uas ua rau nws lub cev tiv thaiv kab mob ua kom muaj peev xwm ua kom nws ua tau zoo evade Class 1 neutralizing antibodies. Ib txoj kev tshawb fawb txhawb kev siv cov tshuaj tiv thaiv COVID-19 kho tshiab nrog cov protein ntau ntxiv los tiv thaiv pej xeem.
Ib qho surge hauv Covid-19 cov xwm txheej tau tshaj tawm nyob rau ntau qhov chaw ntawm lub ntiaj teb. Ib tug tshiab sub-variant JN.1 (BA.2.86.1.1) uas hloov zuj zus los ntawm BA.2.86 variant tsis ntev los no tau ua rau muaj kev txhawj xeeb.
JN.1 (BA.2.86.1.1) sub-variant muaj ib qho kev hloov pauv ntxiv (S: L455S) piv rau nws cov precursor BA.2.86. Qhov no yog qhov kev hloov pauv ntawm JN.1 uas ua rau nws muaj peev xwm tiv thaiv kab mob tiv thaiv kab mob ua kom nws ua tau zoo evade Class 1 neutralizing antibodies. JN.1 tseem muaj peb qhov kev hloov pauv hauv cov protein uas tsis yog S. Zuag qhia tag nrho, JN.1 tau nce kev kis tau thiab tiv thaiv kev tiv thaiv kev muaj peev xwm1,2.
Cov tshuaj tiv thaiv COVID-19 tau dhau los ntev txij li kev kis thoob qhov txhia chaw thiab tau hloov kho nrog rau kev siv cov kab mob sib kis kom tau raws li cov kev cov nyom uas tshwm sim los ntawm cov hloov tshiab tshiab.
Ib txoj kev tshawb fawb tsis ntev los no qhia tias qhov hloov kho monovalent mRNA tshuaj tiv thaiv (XBB.1.5 MV) muaj txiaj ntsig zoo hauv kev txhawb nqa cov tshuaj tiv thaiv kab mob ntshav qab zib kom tsis muaj zog tiv thaiv ntau yam sib txawv xws li tawm tsam JN.1. Txoj kev tshawb no txhawb nqa kev siv cov tshuaj tiv thaiv COVID-19 kho tshiab nrog cov protein ntau ntxiv los tiv thaiv pej xeem3.
Yog tias JN.1 sub-variant nthuav tawm qhov kev pheej hmoo ntxiv rau pej xeem kev noj qab haus huv txheeb ze rau lwm yam kev hloov pauv tam sim no, CDC hais tias tsis muaj pov thawj4.
***
References:
- Yaj S., thiab al 2023. Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure. Preprint bioRxiv. Tshaj tawm Kaum Ib Hlis 17, 2023. DOI: https://doi.org/10.1101/2023.11.13.566860
- Koj Y., thiab al 2023. Virological features of SARS-CoV-2 JN.1 variant. Preprint bioRxiv. Tshaj tawm Lub Kaum Ob Hlis 09, 2023. DOI: https://doi.org/10.1101/2023.12.08.570782
- Wang Q. thiab al 2023. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against emerging SARS-CoV-2 variants. Preprint bioRxiv. Tshaj tawm Lub Kaum Ob Hlis 06, 2023. DOI: https://doi.org/10.1101/2023.11.26.568730
- Lub Chaw Tswj Kab Mob. Update on SARS-CoV-2 Variant JN.1 Being Tracked by CDC. Muaj nyob ntawm https://www.cdc.gov/respiratory-viruses/whats-new/SARS-CoV-2-variant-JN.1.html
***
 is hallmark mutation of JN.1 sub-variant which significantly enhances its immune evasion capability enabling it to effectively evade Class 1 neutralizing antibodies. A study supports use of updated COVID-19 vaccines with spike protein to further protect the public.){kind=link}